The Growing Interest in Psychedelic-Assisted Mental Healthcare
Psychiatrist Karel Scheepstra and colleagues have observed a rising patient interest in psychedelics like LSD and psilocybin – the active component in magic mushrooms and truffles – fueled by frustration with conventional treatment timelines. “we’re seeing vulnerable patients,already on waiting lists for care,taking matters into their own hands,” explains scheepstra.While many are seeking alternative solutions, one psychedelic treatment is currently available within the healthcare system for those who haven’t responded to conventional antidepressants.
A Regulated Option: Esketamine
Esketamine, a derivative of ketamine, is the only psychedelic currently approved for treating depression. Administered as a nasal spray and covered by basic healthcare packages, it’s reserved for individuals who have already tried and failed to find relief with at least three other treatments. Scheepstra notes a concerning trend: “Patients, after only one or two unsuccessful treatments, are drawn to self-experimentation with psychedelics after reading about their potential.”
Unlike traditional antidepressants, esketamine’s effectiveness stems from a dual action. It leverages its mind-altering properties and functions as a medication, stimulating the creation of new neural connections in the brain. “This rewiring is likely what contributes to long-term improvements in depressive symptoms,” Scheepstra states. “It’s not a cure-all, but it represents a significant advancement.”
Navigating the Risks: The Importance of Professional Guidance
However, access to esketamine is carefully controlled. Treatment is only provided in hospitals or mental health institutions, emphasizing the need for professional supervision. Scheepstra and his colleagues are issuing warnings against unregulated “truffle coaches,” “trip therapists,” and “keta clinics” that offer psychedelic experiences without proper medical oversight.
The unsupervised use of psychedelics carries substantial risks. A “bad trip” can lead to a loss of control and dissociation – a feeling of detachment from one’s body, mind, and emotions. “It’s like an out-of-body experience,” Scheepstra describes. “This can be profoundly frightening and induce panic, particularly for first-time users.” In severe cases, a trip can be deeply overwhelming, exacerbating existing anxiety and even triggering suicidal thoughts.
The Future of Psychedelic Research
While esketamine demonstrates positive outcomes when administered responsibly, research into other psychedelics continues. However, progress is hampered by logistical challenges and regulatory hurdles. “Other psychedelics show promise, but haven’t yet been approved by national health authorities,” Scheepstra clarifies. He strongly advises individuals struggling with depression to discuss potential options with their doctor or qualified healthcare provider, and cautions against self-treating with psychedelics.
